Table 1.
Phage Display-derived antibodies that have been approved for clinical use.
| Name | Commercial Name | Format | Target | Company | Clinical Indication | Status | Phage Display Type |
|---|---|---|---|---|---|---|---|
| Adalimumab | HUMIRA | Human IgG1 | TNFα | Abbvie | Crohn’s disease, Rheumatoid arthritis, Colitis ulcerative, Psoriatic arthritis, others. | Market | Naive human Fab library |
| Anti-MIF (BaxF07) | Human IgG4 | Myostatin | Baxter | Muscle loss | Withdrawn | Naive human Fab Library | |
| Atezolizumab * | Tecentriq | Humanized IgG1 | PD-L1 | Roche, Genentech | Cancers, Melanoma, Solid Tumors, hepatocellular carcinoma, others | Market | Human Library |
| Avelumab * | Bavencio | Human IgG1 | PD-L1 | Merck, Pfizer | Renal cell carcinoma, ovarian cancer, gastric cancer, | Clinical Trials. Market: Renal carcinoma | Naive Fab library |
| Belimumab | Benlysta | Human IgG1 | TNFSF13B | GSK, HGSI | Systemic lupus erythematosus (SLE), vasculitis | Market: SLE; Phase III: Vasculitis | Human naive scFv library |
| Brodalumab | Kyntheum, Siliq |
Human IgG2 | IL-17RA | Valeant Pharmaceuticals; LEO Pharma | Plaque psoriasis | Market | MorphoSyś HuCAL |
| Ecallantide | Kalbitor | Not Antibody | Plasma kallikrein |
Dyax Corp. | Hereditary angioedema | Market | Dyax platform |
| Emapalumab | Gamifant | Human IgG1 | IFNγ | NovImmune | Primary hemophagocytic lymphohistiocytosis | Market | Human scFv libraries |
| Faricimab | Vabysmo | Human/Humanized IgG1 | VEGF-A, Ang-2 | Roche | Macular degeneration | Approved | Synthetic human Fab library |
| Guselkumab | TREMFYA™ | Human IgG1 | IL23A | Morphosys (Germany); Morphosys and Janssen Biotech (USA) | Psoriatic arthritis, psoriasis, palmoplantar pustulosis, others | Approved | MorphoSyś HuCAL |
| Ixekizumab | Taltz | Humanized IgG4 | IL17A | Eli Lilly (USA) | Plaque psoriasis, psoriatic arthritis | Market | Immune murine Fab library |
| Lanadelumab | Takhzyro | Human IgG1 | Plasma kallikrein |
Dyax Corp | Hereditary angioedema attacks | Market | Naive human Fab library |
| Necitumumab * | PORTRAZZA™ | Human IgG1 | EGF Receptor | Eli Lilly (USA) | Non-small-cell lung cancer, metastatic colorectal cancer | Approved | Naive Fab library |
| Moxetumomab * | LumoxitiTM | Mouse Exotoxin A-IgG1 | CD22 | MedImmune/Astrazeneca | Hairy cell leukemia | Approved | scFv library |
| Caplacizumab | CapliviTM | Humanized VHH | VWF | Sanofi/Ablynx | Thrombotic thrombocytopenic purpura | Approved | Immune camelid nanobody library |
| Inebilizumab | Uplizna | Humanized IgG1 | CD19 | AstraZeneca/ Medimmune, Viela Bio |
Neuromyelitis optica spectrum disorder | Approved | |
| Ramucirumab * | CYRAMZA™ | Human IgG1 | VEGF Receptor 2 | Eli Lilly (USA) | Breast cancer, gastric cancer, lung cancer, metastatic colorectal cancer, others | Approved | Naive Fab library; Dyax platform |
| Ranibizumab | Lucentis | Humanized Fab | VEGF-A | Genentech | Neovascular (wet) age-related macular degeneration | Market | Fab library |
| Raxibacumab | ABthrax® | Human IgG1 | Anthrax protective antigen (PA) | GlaxoSmithKline (UK); Human Genome Sciences Inc (HGSI/USA) | Anthrax inhalation | Market | Naive human scFv library; CAT platform |
| Relatlimab * | Opdualag | Human IgG4 | LAG-3 | Bristol-Myers Squibb | Melanoma | Approved | Naive human scFv phage library |
| Tafasitamab * | Monjuvi | Humanized IgG1/2 | CD19 | Xencor | Non-Hodgkin’s lymphoma, chronic lymphocytic leukemia | Approved | MorphoSyś HuCAL |
| Regdanvimab | Regkirona | Human IgG1 | SARS-CoV-2 (spike) | Celltrion Healthcare Hungary Kft | COVID-19 | Approved | Human scFv library |
| Tebentafusp * | KIMMTRAK | Human TCR-scFv | gp100, CD3 | Immunocore | Metastatic uveal melanoma | Approved | Synthetic TCR-phage library |
| Tralokinumab | Adbry™ (USA); Adtralza® (EU) | Human IgG4 | IL-13 | LEO Pharma | Atopic dermatitis, asthma |
Approved | Synthetic human scFv library |
TNFα: Tumor necrosis factor alpha. IFNγ: Interferon gamma. VEGF: Vascular endothelial growth factor. EGF: Epidermal growth factor. Ang-2: Angiopoietin 2. LAG-3: Lymphocyte-activation gene 3. IL: Interleukin. PD-L1: Programmed death ligand. VWF: Von Willebrand factor. gp100: A melanoma-associated antigen. Asterisk: Phage-Display-derived antibodies approved for cancer and other clinical applications.